CERo Therapeutics is pioneering a novel approach to cancer treatment through its CER T-cell platform, which integrates the anti-tumor capabilities of both the innate and adaptive immune systems into a single engineered T cell. This innovative technology utilizes chimeric engulfment receptors (CERs) that specifically target "Eat Me" signals present on the surface of cancer cells. By combining direct cell killing with phagocytic antigen presentation, CER T cells aim to enhance tumor control in both hematologic malignancies and solid tumors. This multimodal strategy not only seeks to improve the efficacy of cellular immunotherapy but also addresses the challenges associated with current therapies, such as toxicity and the need for specific tumor-associated antigens.

The therapeutic potential of CERo's platform lies in its ability to recognize a broad range of tumor types and leverage the body's natural immune clearance mechanisms. By enhancing T-cell cytotoxic effects and incorporating antigen-presenting cell-like capabilities, CER T cells can amplify the anti-tumor immune response. This approach allows for rational combinations with other therapeutic agents, potentially leading to more durable and curative outcomes for patients. The integration of insights from synthetic and T cell biology further positions CERo's technology as a promising advancement in the field of cancer treatment, with the potential to overcome existing limitations of current cellular therapies.

United States

At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for oncology. Armed with an understanding of cellular clearance and molecular immunology, we engineer cells to engage new and complementary cell elimination pathways to enable deeper and more sustained clinical responses to maximize wellness.

CERo Therapeutics

Company Details